Serna Bio

🗓 Founded 2021👥 16 employees💰 Last funded Jan 2021
Biotechnology Research
LinkedIn
An estimated 85% of the ~3 billion base pairs in the human genome is transcribed into RNA, but only ~1.5% of these code for proteins. While the chemical properties of protein binders are increasingly understood and interrogated, the field of RNA-targeted drugs is relatively new and the properties of small molecules that drive specific and selective targeting of RNA, and associated assays, are yet to be developed. At Serna Bio [previously Ladder Therapeutics] we are using an AI enabled, data-first approach to write the rules that define RNA-small molecule interactions. Our Discovery Platform powers our first-in-class small molecule programs targeted at classically undruggable proteins and non-coding RNA targets, targeting both human and non-human biology.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2021
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United Kingdom
1
Frequently asked questions
Who invested in Serna Bio?
Serna Bio has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Serna Bio last raise funding?
The most recent investment in Serna Bio recorded on gritt.io was in January 2021.
When was Serna Bio founded?
Serna Bio was founded in 2021.
What industry is Serna Bio in?
Serna Bio operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.